MEREO BIOPHARMA GROUP PLC ADR reports a Return on Equity (ROE) of -104.83%.

What is MREO's dividend yield?

MEREO BIOPHARMA GROUP PLC ADR offers a dividend yield of 0.00%.

What is MREO's Deepscope Quality Score?

Deepscope rates MREO's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy MREO?

Deepscope's AI Timing Score for MREO is 51 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does MREO belong to?

MEREO BIOPHARMA GROUP PLC ADR is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

Cổ phiếu MREO (NASDAQ) | MEREO BIOPHARMA GROUP PLC ADR

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-04 | FS: 2026-03-31)

MREO

MEREO BIOPHARMA GROUP PLC ADR

US:NASDAQ STOCK Healthcare >> Biotechnology News 59

USD 0.32

-0.02 (-4.85%) Day Change

Watchlist Portfolio Compare Chart

0.19

D/E

-104.8%

ROE

-87.9%

ROA

0.00%

Div Yield

MEREO BIOPHARMA GROUP PLC ADR
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.32 Price -0.02 (-4.85%) Day Change	NEWS SCORE: 59

MREO Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 23) và Thời điểm mua ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
Tăng trưởng ROE là âm trong năm ngoái.
ROA quá thấp so với ROE
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt , ...

Yếu tố Chất lượng

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	59
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.32
PBV / Sector	1.59 / 4.58 GOOD
Earning Per Share	-0.21

PE / Sector	N/A / 17.10
PEG or PE/Growth / Sector	N/A / 0.52
Average 1M Daily Value	2.11 M GREAT
Average 1W Daily Value	1.64 M GREAT

Yếu tố Kỹ thuật

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

47%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-7,139.75 / 450.23
NPM Average (%) / Sector	-4,651.27 / -1,506.33
NPM Change Average (%) / Sector	N/A / 4,941.30
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-87.90 / 30.58
ROA Average (%) / Sector	-66.89 / -347.17
ROA Change Average (%) / Sector	16.67 / 5,125.52 GOOD
ROE (%) / Sector	-104.83 / -3.58
ROE Average (%) / Sector	-83.68 / 40.65
ROE Change Average (%) / Sector	9.88 / 2,109.80
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.50
Dividend Change Average (%) / Sector	N/A / 5.02

Chi tiết đăng ký

Analyze Date	2026-06-05 09:12:05
Symbol	MREO
Name	MEREO BIOPHARMA GROUP PLC ADR
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	159.62 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	54.17 / 8,655.90

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: One Cavendish Place, London, United Kingdom, W1G 0QF

Phone: 44 33 3023 7300

Website: https://www.mereobiopharma.com

Sector: Healthcare >> Biotechnology

Description: Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.